XML 53 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Oct. 31, 2015
Jun. 18, 2013
Significant Accounting Policies [Line Items]          
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001      
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 19,778,424 18,850,724 10,675,304    
Revenues, Total $ 4,364 $ 3,523 $ 0    
Brazil [Member]          
Significant Accounting Policies [Line Items]          
Percentage of Adult Gaucher Patients Treated with Uplyso 10.00%        
Subsidiaries [Member] | Sales Revenue, Goods, Net [Member]          
Significant Accounting Policies [Line Items]          
Revenues, Total $ 4,000        
Brazil Agreement [Member] | Subsidiaries [Member] | Fiocruz [Member]          
Significant Accounting Policies [Line Items]          
Purchase Amount To Be Satisfied To Receive Entitled Rights         $ 280,000
Agent Fee, Percentage Of Net Proceeds 5.00%        
Pfizer Agreement [Member] | Pfizer Incorporation [Member]          
Significant Accounting Policies [Line Items]          
Collaborative Arrangement Revenues and Expenses Sharing Percentage 60.00%        
Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member]          
Significant Accounting Policies [Line Items]          
Collaborative Arrangement Revenues and Expenses Sharing Percentage 40.00%        
Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]          
Significant Accounting Policies [Line Items]          
Collaborative Arrangement Revenues and Expenses Sharing Percentage       100.00%